Page 18 - BH-2-4

Brain & Heart Cardiac sarcoidosis with AVB and VA

33. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. with an implantable cardiac defibrillator. J Interv Card
Corticosteroid therapy for cardiac sarcoidosis: A systematic Electrophysiol. 2015;43:55-64.
review. Can J Cardiol. 2013;29:1034-1041.
doi: 10.1007/s10840-015-9978-3
doi: 10.1016/j.cjca.2013.02.004
43. Mactaggart S, Ahmed R. The role of ICDs in patients with
34. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants sarcoidosis-A comprehensive review. Curr Probl Cardiol.
of long-term survival in Japanese patients with cardiac 2024;49(5):102483.
sarcoidosis treated with prednisone. Am J Cardiol. doi: 10.1016/j.cpcardiol.2024.102483
2001;88:1006-1010.
44. Mathijssen H, Bakker ALM, Balt JC, et al. Predictors
doi: 10.1016/s0002-9149(01)01978-6
of appropriate implantable cardiac defibrillator therapy
35. Gallegos C, Oikonomou EK, Grimshaw A, Gulati M, in cardiac sarcoidosis. J Cardiovasc Electrophysiol.
Young BD, Miller EJ. Non-steroidal treatment of cardiac 2022;33:1272-1280.
sarcoidosis: A systematic review. Int J Cardiol Heart Vasc. doi: 10.1111/jce.15484
2021;34:100782.
45. Azoulay LD, Waintraub X, Haroche J, Amoura Z, Cohen
doi: 10.16/j.ijcha.2021.100782
Aubart F. Factors associated with implantable cardioverter
36. Ahmed R, Okafor J, Azzu A, et al. The role of infliximab defibrillators appropriate therapy in cardiac sarcoidosis:
in treating refractory cardiac sarcoidosis. Eur Heart J. A meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis.
2023;44(Supplement_2):ehad655.978. 2020;37:17-23.
doi: 10.1093/eurheartj/ehad655.978 doi: 10.36141/svdld.v37i1.8271
37. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 46. Franke KB, Marshall H, Kennewell P, et al. Risk and predictors
2017 AHA/ACC/HRS guideline for management of patients of sudden death in cardiac sarcoidosis: A systematic review
with ventricular arrhythmias and the prevention of sudden and meta-analysis. Int J Cardiol. 2021;328:130-140.
cardiac death: Executive summary: A Report of the American
College of Cardiology/American Heart Association Task doi: 10.1016/j.ijcard.2020.11.044
Force on Clinical Practice Guidelines and the Heart Rhythm 47. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter
Society. Circulation. 2018;138(13):e210-e271. ablation of ventricular tachycardia in cardiac sarcoidosis:
Report from a multicenter registry. Heart Rhythm.
doi: 10.1016/j.jacc.2017.10.054
2009;6:189-195.
38. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC
guidelines for the management of patients with ventricular doi: 10.1016/j.hrthm.2008.10.039
arrhythmias and the prevention of sudden cardiac death. 48. Siontis KC, Santangeli P, Muser D, et al. Outcomes associated
Eur Heart J. 2022;43:3997-4126. with catheter ablation of ventricular tachycardia in patients
with cardiac sarcoidosis. JAMA Cardiol. 2022;7:175-183.
doi: 10.1093/eurheartj/ehac262
doi: 10.1001/jamacardio.2021.4738
39. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC
Guidelines on cardiac pacing and cardiac resynchronization 49. Berte B, Sacher F, Venlet J, et al. VT recurrence after ablation:
therapy. Eur Heart J. 2021;42(35):3427-3520. Incomplete ablation or disease progression? A multicentric
European study. J Cardiovasc Electrophysiol. 2015;27:80-87.
doi: 10.1093/eurheartj/ehab364
doi: 10.1111/jce.12858
40. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis:
Electrophysiological outcomes on long-term follow-up 50. Stevenson WG, Soejima K. Catheter ablation for ventricular
and the role of the implantable cardioverter-defibrillator. tachycardia. Circulation. 2007;115:2750-2760.
J Cardiovasc Electrophysiol. 2013;25:171-176.
doi: 10.1161/circulationaha.106.655720
doi: 10.1111/jce.12302
51. Muser D, Santangeli P, Pathak RK, et al. Long-term outcomes
41. Nordenswan HK, Pöyhönen P, Lehtonen J, et al. Incidence of catheter ablation of ventricular tachycardia in patients
of sudden cardiac death and life-threatening arrhythmias with cardiac sarcoidosis. Circ Arrhythm Electrophysiol.
in clinically manifest cardiac sarcoidosis with and without 2016;9:e004333.
current indications for an implantable cardioverter doi: 10.1161/CIRCEP.116.004333
defibrillator. Circulation. 2022;13:964-975.
52. Ahmed R, Dulay MS, Liu A, et al. Comparing outcomes of an
doi: 10.1161/CIRCULATIONAHA.121.058120
“early” versus “late” diagnosis of cardiac sarcoidosis following
42. Kron J, Sauer W, Mueller G, et al. Outcomes of patients with a baseline presentation of high-grade atrioventricular block.
definite and suspected isolated cardiac sarcoidosis treated Curr Probl Cardiol. 2024;49(7):102577.

Volume 2 Issue 4 (2024) 12 doi: 10.36922/bh.3515